Mark Stevenson

Senior Partner @FlagshipPioneer Board member @IRProducts @HarbingerHlth @UltimaGenomics | Senior Advisor @Generalatlantic | Former EVP & COO @thermofisher

[andrewdudum @AndrewDudum]

Blood collection is one of the most common reasons people see a doctor – and also one of the most stressful.

Today, we announced an agreement to acquire @yourbio_health, the pioneers behind what we believe to be the world’s most advanced, pain-free blood sampling technology. Using microneedles thinner than an eyelash, their devices produce high-quality capillary samples in a matter of seconds — no blades, no stress.

The future of health innovation will be shaped by technologies that make wellness simpler, more accessible, and more human — and we’re excited to build it together with YourBio.

https://t.co/d0Z7JCk1Dc

[Ultima Genomics @UltimaGenomics]

Ultima is thrilled to announce that the UG 100 sequencer has been selected by the UK Biobank to be the sequencing technology for the largest human proteome project in the world.

PR link: https://t.co/kEvDIEn65W

#NGS #Proteomics #UG100

[Ultima Genomics @UltimaGenomics]

Ultima is excited to welcome Mark Stevenson to our Board of Directors, bringing more than 30 years of experience and leadership in the Life Sciences sector.

https://t.co/CWGcxjqRMF

[Mark Stevenson @camilluslife]

Interview in @PEI_news on the strong opportunity set in growth-stage life sciences companies developing new technologies and solutions that will disrupt the future of the industry.

[General Atlantic @generalatlantic]

GA Global Head of Life Sciences, Brett Zbar, recently spoke with @PEI_news on the wide-reaching secular shifts driving opportunities for life science companies and how GA’s growth-oriented approach seeks to support innovation in the life sciences space.

[Mark Stevenson @camilluslife]

Oxford Immune Algorithmics are applying Artificial General Intelligence to tackle disease and enable decentralised, #precisionmedicine. @algocyte is an AI-driven solution to monitor people’s health with minimally invasive intelligent blood testing & lifestyle data collection

[algocyte @algocyte]

Very excited to announce @camilluslife is joining as an investor to lead our EIS investment round as we continue to focus on commercialising our platform, Algocyte. Mark has a proven track record of growing life sciences businesses https://t.co/DgoUOTX0nJ #MEDTECH #AI

[Mark Stevenson @camilluslife]

Excited to join @generalatlantic as a Senior Advisor. I look forward to the opportunities ahead supporting GA's #LifeSciences team and the disruptive growth companies they back

[General Atlantic @generalatlantic]

GA is thrilled to welcome @camilluslife as a Senior Advisor, specifically supporting #LifeSciences. We look forward to Mark's extensive experience driving strategic growth of Life Sciences businesses as we seek opportunities for innovation across the sector.

[Thermo Fisher @thermofisher]

Thermo Fisher is excited to announce we completed the acquisition of @TheBindingSite, a global leader in specialty diagnostics. Together, we will enable greater innovation for the benefit of patients and customers. Learn more here: https://t.co/eNT6uwIytY

[Mark Stevenson @camilluslife]

As Chair of @TheBindingSite board, and knowing the capabilities of @thermofisher deeply, I'm excited by the agreement to combine will accelerate the innovation and patient reach for pioneering blood cancer diagnosis and monitoring solutions https://t.co/GWf8m5bAbt

[Mark Stevenson @camilluslife]

Agree with perspective on why AlphaFold won’t revolutionize drug discovery - good predictions & useful ones - obtaining actual data (from x-ray, NMR, cryoEM) - the only way to be sure how correct they are and in the end

[Chemistry News @ChemistryNews]

Why AlphaFold won’t revolutionise drug discovery https://t.co/24Wgjac8hM

[Mark Stevenson @camilluslife]

Ingersoll Rand $IR is driven by an entrepreneurial spirit and ownership mindset. They think and act like owners. They are part of the #employeeownership movement with broad-based equity ownership and employee engagement program https://t.co/Q6iHo4WBlb

[Mark Stevenson @camilluslife]

I'm excited to join the seed investor group @RelationRx pioneering based in the Knowledge Quarter in London using active-graph machine learning (ML) combined with single-cell analysis and deep clinical insights for drug discovery

[Relation @RelationRx]

Today, we’re pleased to announce two executive appointments and a $25 million seed financing that will enable us to scale our platform and advance therapeutic candidates.

Learn more: https://t.co/wG8prnqfv0 #computationalbiology #drugdevlopment

[Mark Stevenson @camilluslife]

My final week with @thermofisher. I've been fortunate to be part of many impactful technology innovations in Life Sciences enabling a better understanding of disease biology, novel therapies, and diagnostics.

[Mark Stevenson @camilluslife]

Optimizing clinical trials by deploying machine learning-based insights @thermofisher PPD TrueCast combines extensive patient recruitment and site performance data with predictive models and advanced analytics to optimize site selection, trial enrollment & study cycle times.

[MedCity News @medcitynews]

2 collaborations – CVS Health with Medable, and Thermo Fisher Scientific with Medidata Acorn AI – seek to improve clinical trials https://t.co/yW1AajTUHz

[Mark Stevenson @camilluslife]

Important work from @permedcoalition bringing leaders from multiple sectors of the health care ecosystem to develop a fuller definition of the clinical utility of genomic testing in cancer care #precisionmedicine

[Thermo Fisher @thermofisher]

We're excited to collaborate with @OncocyteCorp to help expand the number of cancer patients benefiting from personalized medicine by making sequencing-based testing simple and more accessible. Learn more here: https://t.co/oUGrvX6bdn

[Olaris, Inc. @OlarisBoR]

We are delighted to announce our partnership with @thermofisher to continue work on a #metabolomics diagnostic assay to assess immune response in #transplant recipients. https://t.co/ojfDoYG8aD

[Thermo Fisher @thermofisher]

We are delighted to announce our role as a Founding Industry Member of Our Future Health - the UK’s largest ever health research programme. We share their goal of the transformation of the prevention, detection and treatment of diseases. @ukfuturehealth
https://t.co/s3jiPi8XS2

[Mark Stevenson @camilluslife]

It is increasingly important to reach patient populations directly. Today at #JPMHC22 I shared some of the learnings from @thermofisher ReadyCheckGo #COVID19 testing partnership with @Color to bring testing directly to schools and employers

[Color @Color]

Meet us where we are —> at #JPM22. Join @othman for a discussion about the innovative models that are making healthcare accessible anywhere. Learn how we're reaching communities in everyday contexts and shifting industry standards to more scalable solutions.

—> Tuesday, 9AM PT

[Thermo Fisher @thermofisher]

We’ve completed our acquisition of @PeproTech a leading manufacturer of recombinant proteins. Peprotech's portfolio complements our existing bioprocessing and cell culture technologies, creating an integrated offering for our customers. Learn more: https://t.co/2xe2CPTfaH

[Mark Stevenson @camilluslife]

Clear description from @Tuliodna on how @thermofisher TaqPath assay can be used to track #Omicron. Thanks for all the great world from you and your colleagues.

[Tulio de Oliveira @Tuliodna]

Main points: 1 - Early identification of Omicron and validation of the S-gene drop-off in South Africa allows countries to track this variant quickly by using a simple qPCR test by Thermo Fisher Scientific.